Patient & Visitor InformationContact Us
  • Hematology Protocols

  • Acute Myelogenous Leukaemia (AML)

    1. LS-P-TRC117146: A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects with Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy
      PI: Eric Winer, MD
      Sites: Rhode Island Hospital
      Learn more about this study


    1. BrUOG HEM-273: Cellular Immunotherapy For Refractory Hematological Malignancies: A Brown University Oncology Research Group Study
      PI: Peter Quesenberry, MD
      Sites: Rhode Island Hospital, The Miriam Hospital
      Learn more about this study